Axsome Therapeutics AXSM Balipodect — Business Combination Consideration Transferred1

Similar metrics at other companies

BTSGPharmacy Solutions — Business Combination Consideration Transferred1

$27M-9.4%

BAXPerClot — Business​ combination​ consideration​ transferred

$53M—

BIIBBIIB115 — Upfront payment for collaboration agreement

$60M—

WTWUp Front — Business Combination Consideration Transferred1

$1.05B—

BAXPerClot — Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill

$53M—

BAXTransderm Scop — Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill

$84M—

Questions, answered.

What is Axsome Therapeutics's balipodect — business combination consideration transferred1?

Axsome Therapeutics (AXSM) reported balipodect — business combination consideration transferred1 of $10.4M in Q1 2026.

What does balipodect — business combination consideration transferred1 mean?

The total value paid to acquire the business or rights associated with the Balipodect program.

How do you interpret balipodect — business combination consideration transferred1?

An increase indicates significant capital deployment for inorganic growth or pipeline expansion, while a decrease suggests a focus on organic development or a lack of recent acquisitions.

How does balipodect — business combination consideration transferred1 compare across companies?

Comparable to upfront acquisition costs or purchase price allocations for specific drug candidates in other biopharmaceutical companies.